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In locally advanced squamous cell carcinomas of the head and neck (LA-SCCHN),
concurrent chemoradiotherapy is an integral part of multimodality management both
in the adjuvant and in the definitive settings. Although de-intensification strategies
have been propelled to the forefront of clinical research in human papillomavirus (HPV)
positive oropharyngeal cancer, three cycles of 100 mg/m2 cisplatin given every 3 weeks
concurrently with conventionally fractionated external beam radiotherapy represent a
cost-effective and globally accessible treatment option for the majority of LA-SCCHN
cases. Based on four large randomized trials, this regimen has become the non-surgical
standard of care for cisplatin-eligible patients. Nevertheless, the outcomes in terms of
efficacy, toxicity, and compliance have been rather disappointing. Therefore, there is
an unmet need to find a better alternative. With limited support from randomized trials,
weekly low-dose cisplatin regimens have replaced the standard high-dose schedule at
some institutions. Four prospective trials exploring radiotherapy with and without weekly
low-dose cisplatin have been published. Two of them were conducted in the 1980s,
one of which had a negative outcome, the third study provided insufficient information
on toxicity, and the fourth trial had to be prematurely terminated due to poor accrual.
Moreover, the findings of two phase III trials comparing the two concurrent cisplatin
regimens favored the high-dose protocol. We performed a composite meta-analysis
of 59 prospective trials enrolling a total of 5,582 patients. The primary endpoint was
overall survival. Reflecting different radiotherapy fractionation schemes and treatment
intents, three meta-analyses were carried out, one for postoperative conventional
chemoradiotherapy, one for definitive conventional chemoradiotherapy, and one for
definitive altered fractionation chemoradiotherapy. In the former two settings, both
high- and low-dose regimens yielded similar survival outcomes, thus, the primary
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objective was not met. When given concurrently with altered fractionation radiotherapy,
patients treated with high-dose cisplatin had significantly longer overall survival than
those who received low-dose cisplatin. In this article we provide a synthetic view of the
results, discuss the issue of cumulative dose, compare two vs. three cycles of high-dose
cisplatin, and present our three-step recommendations for use of the current standard
of care, high-dose cisplatin, in clinical practice.
Keywords: head and neck cancer, chemoradiotherapy, fractionation, cisplatin, clinical trials, cumulative dose,
practice recommendations
INTRODUCTION
In squamous cell carcinomas of the head and neck (SCCHN),
the prevailing clinical presentation is a locoregionally advanced
(LA) disease stage, for which patients are usually offered a
multimodality approach involving chemoradiotherapy (1, 2).
With the primary intent to eradicate either macroscopic or
microscopic disease, this modality represents a relatively
simple, inexpensive, and broadly available treatment option,
albeit severe acute and late toxicities pose a substantial
burden to the patients (3). Based on four large randomized
trials, conventionally fractionated external beam radiotherapy
with concurrent administration of three cycles of high-dose
cisplatin (100 mg/m2) given once every 3 weeks represents
the current standard in definitive and adjuvant treatment of
LA-SCCHN, as it results in significantly better locoregional
control and/or overall survival relative to radiotherapy
alone (4–7). Nevertheless, concerns about its toxicity and
compliance have made many practicing physicians to opt
for alternative regimens. In routine practice, the options
for possible treatment modifications are limited by existing
guidelines, local logistics, and specific reimbursement policies.
Therefore, individualization of chemoradiotherapy protocols
in LA-SCCHN usually consists in tweaking radiotherapy
parameters in terms of total dose, fractionation, and technique
and chemotherapy parameters like the type of systemic
agent, its peak dose, dose intensity, cumulative dose, and
timing of its delivery. In this scenario, despite a clear lack of
convincing evidence from controlled trials, weekly concurrent
chemotherapy based on low-dose cisplatin gained broader
popularity. The major motivation for this transition has probably
been toxicity concerns and logistic reasons (see further in
the text).
The lack of clinical data, which would legitimize the use
of weekly low-dose cisplatin in chemoradiotherapy protocols
of non-nasopharyngeal LA-SCCHN, prompted us to conduct
a set of meta-analyses scrutinizing high-dose and low-dose
cisplatin regimens. Special care was taken to differentiate
between the definitive and adjuvant settings as well as between
conventional and altered fractionation radiotherapy. The results
were published in two full-text papers (8, 9). The primary aim of
this article is to provide a synthesis of our major findings, putting
them in the context of other relevant publications, to present
recommendations for clinical practice, and to open venues for
future research.
EVIDENCE FROM CONTROLLED TRIALS
According to the inclusion criteria of our meta-analyses
presented below, high-dose cisplatin was defined by a dose of
100 mg/m2 given once every 3–4 weeks for a total of three
doses if combined with conventional radiotherapy or two doses
if combined with altered fractionation radiotherapy. Low-dose
cisplatin was defined by a dose not exceeding 50 mg/m2 given
at weekly intervals for a total of at least six applications in the
case of conventional radiotherapy or at least four applications
if combined with altered fractionation radiotherapy. Definitive
radiotherapy based on conventional fractionation consisted of
standard 2 gray (Gy) daily fractions over 7–7.5 weeks with
weekend breaks reaching a total dose of about 70Gy. In
the adjuvant setting, 60–66Gy were given over 6–6.5 weeks.
Altered fractionation included hyperfractionation, acceleration,
or various combinations thereof, such as concomitant boost
technique or simultaneous integrated boost. In the case of
hyperfractionation, two to three smaller fractions of 1.1–1.2Gy
per day were given over the same total treatment time. In the case
of acceleration, radiotherapy duration was shortened as much as
to 5 weeks by extending the number of daily fractions, usually to
6 per week.
With respect to randomized trials comparing one of the
two cisplatin-based chemoradiation protocols (high-dose three-
weekly or low-dose weekly) vs. radiotherapy only, Tables 1–3
provide a summarizing overview of 9 studies (4–7, 10–
17). Concurrently with conventional radiotherapy, a low-dose
regimen was explored in 1 and 3 studies in the adjuvant
and definitive settings, respectively, whereas the high-dose
regimen was studied in 2 and 3 trials, respectively. From
this perspective, studies focusing on altered fractionation
radiotherapy are lacking. So far, only two trials directly compared
weekly with three-weekly cisplatin (Tables 4–6). Another phase
II/III trial of the Japanese Clinical Oncology Group (protocol
JCOG1008) is ongoing to evaluate the non-inferiority of
concurrent chemoradiotherapy with weekly (7 × 40 mg/m2)
relative to three-weekly cisplatin (3 × 100 mg/m2) in the
adjuvant setting (20).
Post-operative Conventional
Chemoradiotherapy
Between 1984 and 1988, Bachaud et al. randomized 88 patients
to receive irradiation either alone or combined with weekly low-
dose cisplatin. The enrolment was conditioned on histological
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findings of extracapsular extension of tumor in the affected
lymph nodes, but not on infiltration of surgical margins. When
tumor-free margins of at least 5mm were attained, the dose to
the primary site was 54Gy, otherwise it was escalated to 65–
70Gy. At 5 years, overall survival (13 vs. 36%), disease-free
survival (23 vs. 45%), and locoregional control (55 vs. 70%) were
significantly higher in the chemoradiotherapy group, while the
advantage in distant control rate was only numerical (49 vs. 58%).
These improvements came at the cost of increased acute toxicity,
consisting above all of weight loss, mucositis, nausea and/or
vomiting, and myelosuppression. Grade 3–4 adverse events thus
occurred in 16 and 41% of patients treated with radiotherapy and
chemoradiotherapy, respectively, being only partially translated
into long-term severe complications (15 vs. 20%) (10, 16).
Exploring three-weekly cisplatin, the Radiation Therapy
Oncology Group (RTOG) 9501 and the European Organization
for Research and Treatment of Cancer (EORTC) 22931 trials,
were conducted and published about one decade later, relative to
the study by Bachaud et al. Both RTOG 9501 and EORTC 22931
focused on high-risk patient groups. Most importantly, tumor
specimens were characterized by the presence of extracapsular
spread and/or positive margins which, in the case of EORTC
22931, also encompassed close margins up to 5mm. The
intention-to-treat populations consisted of 459 and 334 subjects
in RTOG 9501 and EORTC 22931, respectively. In RTOG
9501, three-weekly cisplatin was associated with a significant
prolongation of 5-year locoregional control (68 vs. 81%) and
disease-free survival (25 vs. 35%), but without significant overall
survival benefit (37 vs. 45%). In the EORTC study, the Kaplan-
Meier estimates of all these three parameters were statistically
improved (locoregional control: 69 vs. 82%; progression-free
survival: 36 vs. 47%, overall survival: 40 vs. 53%). Systemic
treatment with cisplatin had no meaningful impact on the
risk of distant metastasis development in either study; five-year
cumulative incidence ranged between 20 and 25% regardless of
study arm. As expected, severe acute adverse events occurred
more commonly in cisplatin-treated patients with mucositis rates
being 18 vs. 30% and 21 vs. 41% in RTOG 9501 and EORTC
22931, respectively. Further chemotherapy-related side effects
were mostly of hematological and gastrointestinal origin. Not
clearly affected by systemic treatment, severe late toxicity ranged
between 20 and 40% (4, 5, 17).
Looking at the three randomized trials together, there is a
clear shortage of patients treated with weekly cisplatin under
controlled clinical conditions. The high-dose cisplatin regimen
was tested in a cohort almost 10 times larger. As to efficacy,
the three-weekly regimen, again, numerically outperformed its
competitor, though we cannot exclude the possible influence
of stage migration reflected by the higher rate of distant
failures in the earlier, low-dose cisplatin trial. In this respect,
advances in diagnostics might have prevented some patients
with clinically silent distant metastases from participation in
the two subsequent studies with the three-weekly schedule.
Further, appeals to low-dose cisplatin often rest on assuming its
better toxicity profile. Unfortunately, between-trial comparisons
of side-effects are confounded by incomplete and selective
reporting, and evaluation of a number of side effects relies in part
on each physician’s expertise. Nevertheless, paying attention to
patient’s compliance might give us some important clues, because
treatment toxicity plays a role in decreasing adherence to a given
regimen. Bachaud et al. reported that only 59% of the study
population could receive all planned cycles of cisplatin. The two
studies on three-weekly high-dose cisplatin corroborated these
findings with figures slightly above 60%.However, only a rigorous
randomized trial could bring the ultimate vindication addressing
all key aspects of the weekly vs. three-weekly schedules.
In 2012, Tsan et al. published the results of a small phase
III trial randomly assigning 55 patients to one or the other
concurrent cisplatin regimens. Both groups received the same
mean doses of chemotherapy and radiotherapy, but significantly
more patients could tolerate cumulative doses of at least 200
mg/m2 cisplatin in the high-dose arm (18). This threshold seems
to be important, since mounting evidence suggests sufficient
therapeutic effect when such an exposition to cisplatin is
met (21–23). Besides that, despite lower cumulative doses, the
weekly regimen produced more acute toxicity, particularly severe
mucositis. Due to a median follow-up of only 12 months, the
overall survival results remain preliminary with the following
rates at 1 year: 79.3% with the three-weekly high-dose regimen
vs. 71.6% with weekly cisplatin (p= 0.978) (18).
Another stream of evidence bolstering the three-weekly
regimen came recently from a large randomized trial from
India with 300 patients (19). The design was similar to the
previous study except for the following major differences: (1) the
investigators used a lower planned cumulative dose of weekly
cisplatin (6–7 × 30 vs. 7 × 40 mg/m2 in the Tsan et al. trial)
which might have compromised the comparison with 3 × 100
mg/m2 of three-weekly cisplatin; (2) patients could be treated
both in the adjuvant and the definitive setting, although in the
end, 93% belonged to the former group; and (3) all major SCCHN
subsites (oral cavity, oropharynx, hypopharynx, larynx) and also
patients with cervical lymphadenopathy of unknown primary
could enter the study, although in the end, 87% subjects had oral
cavity cancer, while Tsan et al. focused exclusively on oral cavity
cancer (18, 19).
It is also of interest that in addition to positive surgical
margins, the Indian trial accommodated cases with close margins
(≤ 5mm) which, as noted above, might steer the outcome.
After a median follow-up of 22 months, the primary endpoint,
estimated cumulative 2-year locoregional control, was improved
by 14.6% in the three-weekly cohort (58.5 vs. 73.1%, p = 0.014).
The resulting gains in median progression-free survival (17.7 vs.
28.6 months) and overall survival (39.5 months vs. not reached)
fell short of statistical significance. The enhanced efficacy of
the three-weekly regimen, albeit possibly influenced by the
difference in cumulative doses, was offset by a higher incidence
of acute adverse events (71.6 vs. 84.6%, p= 0.006), specifically in
terms of vomiting, infection, hearing disturbance, hyponatremia,
and myelosuppression. Occurring at a rate between 10 and
14%, severe chronic toxicity did not appear to be affected by
the study medication. Remarkably, there were no significant
differences between the two arms of the study in terms of
treatment completion and compliance to the therapy (p = 0.1).
Only 13.3% of patients did not receive the third cycle in the
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high-dose three-weekly arm for reasons of toxicity or patient
refusal, while the 7th cycle in the low-dose weekly arm could
not be given in 9.3% for toxicity reasons. Importantly, the
number of administered chemotherapy cycles was influenced
by the fact that 60Gy of radiotherapy were planned in the
prevailing adjuvant setting and the resulting six-week course
usually finished before the last scheduled date of chemotherapy.
Consequently, not more than two thirds of those treated with
high-dose cisplatin could receive all three cycles and only slightly
more of those allocated to the low-dose arm could benefit from
all 7 cycles (19).
In summary, admitting a more rigorous scientific design of
randomized comparative studies is still needed, post-operative
use of three-weekly high-dose cisplatin given concurrently
with conventionally fractionated radiotherapy in LA-SCCHN
seems unassailable.
Definitive Conventional
Chemoradiotherapy
Three randomized trials with altogether 746 patients in
the intention-to-treat population were conducted to evaluate
the benefit of concurrent weekly low-dose cisplatin added
to definitive conventional radiotherapy. In the first, Eastern
Cooperative Oncology Group (E2382) study from Quon and co-
workers, the accrual period began in 1982, about 20 years prior
to the start of the latter two studies, authored by Ghosh-Laskar
et al. and by Sharma et al. Between these three trials, there was a
clear difference in the chosen target cumulative dose of cisplatin
(7 × 20 vs. 7–8 × 30 vs. 7 × 40 mg/m2) which undoubtedly
impacted on the observed outcomes. Quon et al. failed to show
a meaningful improvement in the median failure-free survival,
and the median overall survival was even numerically lower in
those treated with combined therapy (13.3 vs. 11.8 months).
Another reason for disappointment stemmed from significantly
higher acute (nausea and/or vomiting, neurologic, renal, and
haematologic), but also chronic (esophageal and laryngeal)
toxicities elicited by weekly cisplatin (12). The three-arm trial
performed by Ghosh-Laskar et al. was underpowered and had
to be prematurely terminated after accruing 199 patients out
of 750 planned enrolments. Despite a small improvement in
locoregional control (p = 0.049), the target cumulative dose of
210–240 mg/m2 did not translate into overall survival advantage
with 5-year rates being 36% in the radiotherapy alone arm
vs. 56% in the combined modality arm (p = 0.112). Severe
acute mucositis, but not skin toxicity was more common in the
altered fractionation and chemoradiotherapy cohorts. Incidence
of distant metastases and late toxicity did not differ among
treatment groups (13). Relative to the E2382 study, Sharma et al.
doubled the cumulative dose which apparently paid off. Echoed
by a clear gain in median overall survival (27 months vs. no
reached, p = 0.02), the complete response rate rose from 67.1 to
80.5% (p= 0.04). The increased severe acute toxicity rested at an
acceptable 40% and was accompanied by a high adherence rate to
cisplatin. No data on late side effects were reported (11).
Another three studies this time exploring the three-weekly
regimen enrolled altogether 970 patients during the 1990s.
Planned doses of chemotherapy (3 × 100 mg/m2 cisplatin)
and radiotherapy (70Gy) were set firmly, but were difficult
to fulfill, especially with respect to cisplatin. Up to 30% of
patients did not receive all planned cycles. Adelstein et al. and
Fountzilas et al. showed a clear prolongation of median overall
survival (from 12.6 to 19.1 months and from 12.2 to 48.6
months, respectively) accompanied by an increase in severe acute
adverse events, notably hematological toxicity and nausea and/or
vomiting, in the treatment arm with cisplatin. All grade 3-4
acute toxicities were as high as 85% in the study by Adelstein
et al.; data on late effects are not publicly available. Contrary
to expectation, compliance with all three cycles of cisplatin
remained high at about 85% (6, 15). Concerning the third trial,
Forastiere et al. set out to determine the value and optimal
timing of chemotherapy as an adjunct to radiotherapy but
strictly in patients with glottic and supraglottic larynx cancer.
Compared with radiotherapy alone, concurrent three-weekly
cisplatin resulted in a significantly better larynx preservation,
locoregional control, and disease-free survival even at 10-
years. Adherence to treatment was slightly inferior than in the
previous two trials. Seventy percent of patients received all three
concomitant cisplatin doses. From long-term view, there was
also a trend toward improvement in distant control (from 76 to
84%), which was, however, not the case in the study reported
by Adelstein et al. with rates about 80% across all treatment
cohorts (6, 7).
We have learned from the interpretation of overall survival in
the study by Forastiere et al. how important it is to report long-
term results in such cases. The first paper from 2003, estimating
5-year overall survival after a median follow-up among survivors
of 3.8 years, came to almost identical figures (about 55%)
across all three treatment cohorts, i.e., radiotherapy alone,
concomitant chemoradiotherapy, and induction chemotherapy
followed by radiotherapy. Alarmingly, as published in 2013,
at a median follow-up of 10.8 years, the survival curves
started dissociating after about 4.5 years from randomization.
This updated publication suggested a worse outcome in the
concomitant compared with induction chemotherapy arm
(p = 0.08), which could not be attributed to larynx cancer
or the treatment itself. Although no significant differences
in the 10-year cumulative rates of grade 3-5 late toxicities
were detected (30–38%), it has been recognized, despite the
extraordinary effort of the investigators to gather meaningful
late toxicity data from this cooperative, multi-institutional study,
that the results are inadequate, and the difference in survival
reflects indeed an increase in delayed adverse events (7, 14).
Radiation technique represents another important variable. As a
general rule, two dimensional and three dimensional treatment
planning has been linked to severe late side effects, which are
rather uncommon in the current era of image-guided intensity-
modulated radiotherapy (IMRT) with or without cisplatin (24).
Anyway, the increase of deaths from non-cancer related causes
is worrisome and places an even greater onus on accurate and
complete reporting of studies.
With the debatable exception of the Indian trial mentioned
in Post-operative Conventional Chemoradiotherapy, no
other prospective studies compared low-dose weekly
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TABLE 7 | Selection criteria pertinent to the composite meta-analysis of weekly low-dose vs. three-weekly high-dose concurrent cisplatin (8, 9).
Key inclusion criteria Key exclusion criteria
1. Full-text articles published up to December 1, 2015 Other language than English
2. Prospective studies Updates and additional investigations of previously reported
patient populations with no new relevant data
3. Locally advanced squamous cell carcinoma of the head and neck
(stage III-IVB)
No standard reporting of efficacy and/or toxicity
4. Treatment-naive tumors >50% of patients had cancer of the nasopharynx or salivary
glands and/or recurrent tumors
5. Concurrent chemoradiotherapy either in the definitive or adjuvant
settings
>25% had incomplete specification of treatment schedule
6. Separate evaluation of conventional and altered fractionation
radiotherapies
>25% treated with induction chemotherapy
7. High-dose protocol during conventional fractionation: 100 mg/m2
cisplatin on days 1, 22, and 43 (alternatively 2, 23, 44)
>25% treated using different time intervals, doses, or routes
of application of cisplatin
8. High-dose protocol during altered fractionation: 100 mg/m2
cisplatin on days 1 and 22 (alternatively 1 and 28)
>25% treated using alternative radiotherapy protocols
9. Low-dose protocol during conventional fractionation: ≤50 mg/m2
cisplatin weekly at least 6x
>25% had cisplatin combined with other drugs
10. Low-dose protocol during altered fractionation: ≤50 mg/m2
cisplatin weekly at least 4x
>25% had chemoradiotherapy in hyperthermia
with high-dose three-weekly concurrent cisplatin in the
definitive setting.
EVIDENCE FROM A META-ANALYSIS OF
59 TRIALS
In two recent papers we analyzed aggregate data from altogether
59 prospective trials to take up the comparison between the two
concurrent cisplatin regimens (8, 9). Consisting of three separate
meta-analyses as explained below, our work offers further insight
into the conundrum of low-dose vs. high-dose cisplatin. Within
the context of available large phase III clinical data favoring more
or less the three-weekly approach, the basic idea was to figure
out which one of the following two hypotheses is suitable for
adoption by the medical community:
(A) The low-dose regimen has more potent anti-tumor
properties than its competitor. Ergo, low-dose cisplatin
should be considered the new non-surgical and/or adjuvant
standard of care in the clinical scenario of LA-SCCHN.
(B) The low-dose regimen does not outperform high-dose
cisplatin. Hence, high-dose cisplatin should remain the
standard of care, while more research is warranted on the
weekly protocol.
Afterwards, the key step was to define the appropriate primary
objective. In this respect, overall survival is generally accepted
as a reliable outcome endpoint. Caution needs to be advised
when interpreting other measures, which may rest on weak
evidence. For instance, different author groups use different
criteria to estimate progression-free or disease-free survival as
well as locoregional or distant control rates. The resulting
heterogeneity impedes data merging and running a proper
meta-analysis. Correspondingly, an inter-trial evaluation of
adverse events and compliance has been confounded by an
incomplete and selective reporting. Moreover, inherent issues
in toxicity data collecting include the distinct aim of the study,
a subjective influence of each physician on the assessment,
individual variations in the emergence of side effects which
may not always coincide with their measurement, and the
existence of different toxicity scales and guidelines. As an
illustration, the highest rate of severe acute laryngeal toxicity
(18%) was noted in the Forastiere et al. study, which focused
specifically on laryngeal preservation. Considering all these
aspects, overall survival was chosen as the reference endpoint in
our meta-analysis.
To reflect the specific biological effects of different
radiotherapy fractionation schedules and to separate the
adjuvant from the definitive treatment intents, three
meta-analyses were carried out, one for postoperative
conventional chemoradiotherapy, one for definitive conventional
chemoradiotherapy, and one for definitive altered fractionation
chemoradiotherapy. Published data were insufficient to run a
meta-analysis in the setting of postoperative altered fractionation
chemoradiotherapy. The paucity of data can be explained by the
fact that relative to conventional fractionation the altered scheme
does not seem to bring any survival advantage after surgical
resection and is even associated with a higher rate of severe acute
mucositis (25). Selection criteria and the flow diagram of study
distribution are detailed in Table 7 and Figure 1, respectively.
Other methodological aspects will not be presented here, as
they have been exhaustively explained in both publications.
The following subsections will cover the most important results
in terms of efficacy, toxicity, and compliance. They set out to
provide a summarizing interpretation with implications for
clinical practice.
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FIGURE 1 | Flow chart of study distribution into three separate meta-analyses (8, 9).
Efficacy
In the frame of conventionally fractionated radiotherapy, no
statistically significant difference in overall survival was observed
between low-dose weekly and high-dose three-weekly cisplatin
(Table 8, Figure 2). This was true for both the adjuvant
(p = 0.5345) and the definitive (p = 0.8519) treatment
settings. But do overlapping survival curves automatically mean
equipotency of the respective regimens? To answer this, several
aspects have to be taken into account. First, it should be kept
in mind that the results originate from a meta-analysis, and not
from a randomized clinical trial. Our meta-analysis comprised
data from trials that were typically uncontrolled or did not
compare low- vs. high-dose cisplatin schedules. Consequently,
the pooled data related to patient groups that were not intended
to be compared prospectively, leading to an increased likelihood
of selection, confounding, and reporting biases. In other words,
the two pooled patient populations treated with either low- or
high-dose cisplatin were not selected according to exactly the
same stratification criteria. Second, there were discrepancies in
treatment adherence expressed as proportion of patients who
received all planned cycles of chemotherapy. In both the adjuvant
and definitive settings, compliance was worse with high-dose
cisplatin (71 vs. 64% and 88 vs. 71%, respectively), although this
difference reached statistical significance only in the latter setting
(p = 0.5747 and p = 0.0017, respectively). Lower compliance
signifies that the mean cumulative dose in a given patient cohort
is also decreased. Thus, it may be speculated that even with
administration of a lower amount of cisplatin correlating with
lower compliance, the high-dose regimen managed to maintain
a sound antitumor activity comparable with its low-dose
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TABLE 8 | Model-based estimates of overall survival according to the three meta-analyses (8, 9).
Overall survival at... Conventional fractionation
Definitive treatment Post-operative treatment
Weekly cisplatin (%) Three-weekly cisplatin (%) Weekly cisplatin (%) Three-weekly cisplatin (%)
1-year 72 73 75 79
2-year 61 61 66 69
3-year 53 52 60 62
4-year 47 45 55 56
5-year 41 39 51 51
Overall survival at... Altered fractionation
Definitive treatment Post-operative treatment
Weekly cisplatin (%) Three-weekly cisplatin (%)
1-year 68a 83a Meta-analysis was not conducted due to an
insufficient number of eligible studies
2-year 55a 74a
3-year 45a 68a
4-year 38a 62a
5-year 33a 57a
aSignificant differences.
FIGURE 2 | Overall survival analysis comparing high-dose vs. low-dose cisplatin given concurrently with conventional (A) and altered fractionation (B) radiotherapy in
the definitive setting. Reprinted in part from Szturz et al. (8). Copyright © 2017, with permission from AlphaMed Press, and from Szturz et al. (9). Copyright © 2018,
with permission from Elsevier.
counterpart. If this is true, then we will be able to show an
improvement in overall survival with a lower planned cumulative
dose of three-weekly cisplatin, where compliance can be expected
to rise.
And this is indeed exactly what happened in the altered
fractionation model. Herein, there was a clear survival advantage
with two cycles of high-dose cisplatin over the low-dose
applications (p = 0.0185; Table 8, Figure 2). This is in line
with compliance outcomes favoring also the high-dose regimen
(71 vs. 92%, p = 0.0353). So numerically, notwithstanding
the use of different radiotherapy techniques, we see a much
better compliance in patients treated with two (92%) in
comparison with three (64–71%) cycles of high-dose cisplatin,
while adherence to low-dose cisplatin remains more consistent
(71–88%). Pertaining to definitive chemoradiotherapy, response
rates were similar between low- and high-dose arms in both
conventional and altered fractionation models (please see for
further details both source publications).
However, proponents of low-dose cisplatin would probably
argue against these conclusions. Their interpretation would
presumably rest on the notion that if low-dose cisplatin exhibits
a comparable survival outcome as the high-dose schedule, both
approaches must be equally effective and can therefore be applied
interchangeably to clinical practice. At this point it should be
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emphasized once again that data from randomized clinical trials,
as debated above, are not sufficient to prioritize the low-dose
over the high-dose protocol, and the absence of a survival
benefit in our composite meta-analysis perfectly affirms this
observation. Further support of our arguments relates to the
fluctuations in treatment adherence and the results in the altered
fractionation chemoradiotherapy.
Toxicity
In each of the three meta-analyses, statistically significant
differences were detected in several acute toxicity parameters,
but not every case is supported by a sufficient number of
source studies. Although weekly cisplatin given concurrently
with postoperative conventional radiotherapy exhibited higher
rate of grade 3-4 dysphagia and weight loss than three-weekly
cisplatin, each of these two findings is based on only one study
in the weekly arm, which is also true for weight loss in the
three-weekly arm (10, 18, 26). In addition, in the one study
on weekly cisplatin reporting severe dysphagia, patients did not
receive hydration routinely (18). More convincingly, in definitive
conventional chemoradiation, the three-weekly protocol clearly
showed higher haematotoxicity (p = 0.0083 for leukopenia
and p = 0.0024 for neutropenia), nausea and/or vomiting
(p < 0.0001), and nephrotoxicity (p = 0.0099), thus typically
cisplatin-related adverse events. But here again, the negative
contribution of the third high-dose cisplatin dose to the observed
acute toxicity can be hypothesized. This explanation may in fact
be plausible. In the altered fractionation setting, where the target
cumulative dose oscillates around 200 mg/m2, corresponding
with two high-dose cisplatin doses, it was the weekly regimen
that was associated with an increased burden of severe acute side
effects. The difference was particularly apparent for mucositis
and/or stomatitis (p = 0.0202), but also concerned constipation
(p = 0.0066). Yet caution is required once more, because the
data on constipation in the weekly regimen was based only on
one study (27).
Acute toxicity closely allies withmortality, where two variables
have been distinguished. One is represented by grade 5 toxicity,
defined as toxic death during chemotherapy or within 30 days
after its completion, the second by 30-day mortality. While both
parameters did not seem to be affected by different cisplatin
scheduling during conventional radiotherapy, low-dose weekly
cisplatin induced significantly more grade 5 adverse events and
a higher 30-day mortality than high-dose three-weekly cisplatin
during altered fractionation radiotherapy. It is tempting to point
out the absence of the third cisplatin cycle as being responsible
for the apparently better results in the three-weekly altered
fractionation arm. On the other hand, the decisive factor might
have also been the altered radiotherapy scheme itself because
of the variety of existing fractionation patterns which could not
be utterly eliminated in the meta-analysis leading to a possible
stratification bias. Moreover, altered fractionation is known to be
more powerful than conventional fractionation (28).
For any treatment with curative intent, accurate recognition,
systematic monitoring, and meticulous reporting of late
adverse events are of paramount importance. The 2013
update on the study by Forastiere et al. includes an illustrative
example to that (14). However, despite the major implications
on quality of life of long-term cancer survivors, chronic
toxicity has often been underreported, and concerns about
the reliability of toxicity data have been risen (29). Entailing
difficulties for interpretation, most of the studies enrolled
in our meta-analyses lack long-term follow-up information.
Analogously to the previously mentioned mortality outcomes,
the only statistical difference was found in altered fractionation
chemoradiotherapy, particularly in severe late subcutaneous
fibrosis, which was significantly more common in one trial of
low-dose cisplatin compared with three studies on the high-dose
regimen (p < 0.0001).
Compliance
Treatment adherence constituted the third touchstone of our
meta-analyses. It accounted partly for the observed differences in
survival as well as reflected those in toxicity.We looked separately
at the compliance to radiotherapy and chemotherapy. With
respect to radiotherapy, both arms achieved comparable results
irrespective of therapy intent or fractionation schedule. This
seems logical, given the equal characteristics of radiotherapy in
both arms of each of the respective meta-analyses, but reporting
this is important to show that the disparities in compliance were
primarily driven by systemic therapy. The only exception was
a trend toward worse radiotherapy compliance in the weekly
altered fractionation arm in terms of completion as prescribed
(p = 0.0659). However, this could be easily explained by the
worse overall tolerance of that arm, because impaired compliance
was also apparent in the analysis of cisplatin administration. In
this respect, it should be remembered that due to the limited
added value of chemotherapy in chemoradiotherapy protocols of
SCCHN, it is the systemic treatment in the first place which is
usually reduced or interrupted in the case of severe acute toxicity.
Unplanned radiotherapy breaks were linked to significantly
worse locoregional control which may decrease as much as by
1.2% for every day of interruption, and this does not seem to be
compensated by the use of chemotherapy (30).
Summing up the topic, which has already been addressed in
the previous sections, in the conventional chemoradiotherapy
meta-analyses, the proportion of patients who received all
prescribed chemotherapy cycles was lower in those treated
with three-weekly cisplatin. In the postoperative setting, this
relationship fell short of statistical significance (71 vs. 64%,
p = 0.5747), but the influence of limited source data in the
weekly arm, stemming from only two studies, cannot be ruled
out. In the definitive setting, the difference was indisputable (88
vs. 71%, p = 0.0017), being backed up by a higher number
of enrolled trials. In contrast, in the meta-analysis of altered
fractionation it was the high-dose protocol reaching better
adherence (p = 0.0353), which might be a consequence of the
specific kinetic pattern of severe acute adverse events usually
peaking at 4–5 weeks after chemoradiotherapy initiation, that
is when two cycles of three-weekly cisplatin have already be
delivered (31, 32).
The primary difference between cisplatin given concurrently
with conventional and altered fractionation radiotherapies is the
cumulative dose which tends to attain 300 and 200 mg/m2,
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respectively. Therefore, subtracting radiotherapy, it may be
hypothesized that the lower cumulative dose, given in an
appropriate schedule, may ultimately yield better outcomes due
to better compliance and lower toxicity.
SPECIAL CONSIDERATIONS
Cumulative Dose
To continue on the subject of cumulative dose, we will mention
several pivotal papers complemented by our own observations.
In a systematic review, Strojan et al. constructed a model
based on 6 phase III trials of definitive chemoradiotherapy.
They demonstrated that regardless of the cisplatin schedule
used (daily, weekly or three-weekly), escalating the dose
of concurrent cisplatin in the range between 140 and 270
mg/m2 was significantly associated with overall survival
(p = 0.027). For every 10 mg/m2 of cisplatin the magnitude
of absolute benefit between combined modality treatment and
radiotherapy alone rose by 2.2% (33). Wong et al. searched the
Longitudinal Oncology Registry of Head and Neck Carcinoma
(LORHAN) for newly diagnosed LA-SCCHN patients treated
with chemoradiotherapy. In a cohort of 1,091 cases, higher
cumulative doses of cisplatin were obtained in those treated with
the high-dose three-weekly schedule than in those treated with
the low-dose weekly cisplatin schedule (p < 0.001) and this had
an impact on overall survival (34). Similar results were achieved
in an unadjusted analysis of 2,901 patients using the population-
based Veterans Affairs dataset (35). However, the outcomes of
the latter two studies must be interpreted with caution because
of their retrospective nature. It cannot be ruled out that patients
in the low-dose weekly arm were less vigorous and more likely
to have their treatment and survival compromised as suggested
by adjusting for performance status of the veterans which
eliminated the initially observed survival difference.
Other investigators have posited that a cumulative dose of
200 mg/m2 cisplatin produces an adequate anti-tumor effect
in terms of overall survival. Their opinion resides on an
indirect comparison with data stemming from randomized
trials of alternative regimens in LA-SCCHN or nasopharyngeal
cancer, on a retrospective observation of patients treated with
weekly cisplatin, on a meta-analysis involving randomized
trials comparing concomitant platinum- and platinum plus
fluorouracil-based chemoradiation vs. radiotherapy alone, and
on a recently published large randomized trial in which the
median total cisplatin dose received in the standard high-dose
arm was 200 mg/m2 (22, 23, 36, 37). Stronger evidence for
this notion was conveyed by the RTOG 0129 phase III trial
assigning patients to receive either two cycles of three-weekly
high-dose (100 mg/m2) cisplatin concurrent with accelerated
radiotherapy or three cycles of the same high-dose cisplatin
with conventionally fractionated radiotherapy (38). Although
no improvement in outcome was seen in one or the other
patient cohort, subgroup testing according to the number of
delivered cisplatin cycles and radiotherapy fractionation merits
further attention. In the overall survival analysis, irrespective of
fractionation, giving only one dose of 100 mg/m2 cisplatin was
significantly worse than any other combination, but no advantage
was seen with three over two cycles of cisplatin. Progression-
free survival turned out alike. Disappointingly, cancer-specific
survival curves by distant metastasis overlapped, regardless of
chemotherapy or radiotherapy characteristics. However, one
of the most intriguing results concerned locoregional control.
Here, three cycles of cisplatin together with conventional
radiotherapy yielded better outcome than one cycle (p = 0.049
for both fractionation schemes), but also than two cycles
(p = 0.047 for altered fractionation and 0.11 for conventional
radiotherapy) (21).
Taken together, a cumulative dose of at least 200 mg/m2
of cisplatin seems to ensure an adequate survival benefit
in comparison with radiotherapy alone, but it is currently
unknown whether a further increase brings additional survival
prolongation or whether this is not offset by escalated toxicity
responsible for an increment in non-cancer related deaths. On
the other hand, good locoregional control, being the possible goal
of cumulative doses around 300 mg/m2, is for sure one of the
paramount factors in these patients. LA-SCCHN affects a region
prone to visible disfigurement with far-reaching functional and
esthetical aspects, and therefore reaching local/regional control
legitimizes full-dose treatment. The cumulative cisplatin dose
issue seems to play a different role in human papillomavirus
(HPV)-positive oropharyngeal cancers, a disease entity with a
rapid rise in incidence in western societies, with a much better
prognosis, and for which we hope that less aggressive therapies
might lead to at least similar outcome as presently obtained with
the standard approach, but with less (acute and late) toxicity (39).
Researchers from Canada and Italy conducted a pooled
analysis of 659 patients with stage III and IV oropharyngeal
cancer, carcinoma of unknown primary, and laryngo-
hypopharyngeal cancer who had been treated between 2000 and
2012 in two tertiary academic cancer centers with single-agent
cisplatin during radiotherapy. All patients were treated with
IMRT or three-dimensional conformal radiotherapy (3DRT)
to a gross tumor dose of 60–70Gy in 33–35 fractions over
6.5–7 weeks (2Gy per fraction). Concurrent cisplatin regimens
were either high-dose 100 mg/m2 three-weekly on days 1, 22,
and 43 or low-dose 40 mg/m2 weekly for 7 weeks, the choice
of which was based on institutional guidelines taking into
account patient factors including Zubrod Performance Scale and
comorbidities. Three-year overall survival for cisplatin <200
mg/m2, equal to 200 mg/m2, and above 200 mg/m2 subgroups
were 52, 60, and 72% (p = 0.001) for the HPV-negative and
91, 90, and 91% (p = 0.30) for the HPV-positive patients. A
multivariate analysis confirmed a survival benefit with cisplatin
above 200 mg/m2 for HPV-negative patients (hazard ratio [HR]
0.5, 95% confidence interval [CI]: 0.3–0.7, p < 0.001) but not
for HPV-positive patients (HR 0.6, 95% CI: 0.4–1.1, p = 0.104).
There was a superior overall survival trend in the HPV-positive
T4 or N3 high-risk subset (N = 107) with cisplatin above 200
mg/m2 (HR 0.5, 95% CI: 0.2–1.1, P = 0.07) (40). Of interest, the
recently reported de-escalation trial RTOG 1016, using 2 cycles
of 100 mg/m2 cisplatin with altered fractionation radiotherapy
in patients with low- and intermediate risk HPV-positive
oropharyngeal cancer, showed superior outcome vs. the same
radiotherapy plus weekly cetuximab (an anti-epidermal growth
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factor receptor [EGFR] monoclonal antibody approved for this
indication) (41).
Two vs. Three Cycles
In the definitive setting, our composite meta-analysis favored
concurrent altered fractionation radiotherapy with two cycles
of high-dose cisplatin. Owing to different radiotherapy
fractionation schedules, an interpretation of a direct comparison
with three-cycles of high-dose cisplatin combined with
conventional radiotherapy would be problematic. Nevertheless,
a compromise solution using absolute values may be worth
pursuing. In this respect, the former regimen achieved higher
overall response rates (89 vs. 80%), complete response rates (74
vs. 60%), overall survival (5-year rates: 57 vs. 51%), and also
compliance with all planned cycles of cisplatin (92 vs. 71%).
Severe adverse events were numerically comparable except
for two parameters. The first was acute dysphagia (40 vs. 26%
in altered fractionation vs. conventional chemoradiotherapy,
respectively), which is not a typically chemotherapy-induced side
effect, but rather being related to differences in fractionation,
and the second was late toxicity (43 vs. 14%, respectively), which
is worth noticing, albeit that, as mentioned earlier, its reporting
is often inaccurate and suffers from further biases.
Conclusions of such an indirect comparison are in line
with the results from our individual meta-analyses. The
only setting where a difference in overall survival was
demonstrated was altered fractionation with high-dose cisplatin
surmounting weekly regimens. Moreover, as alluded to above,
it might have been the third cycle of high-dose cisplatin
responsible for inferior compliance and greater toxicity in
the definitive setting with conventional chemoradiotherapy. In
addition, taking into account the mounting evidence on the
significance of cumulative dose, the long-term RTOG 0129
trial data, and the recently reported outcome of RTOG 1016,
it may follow that a minimum of two cycles of 100 mg/m2
cisplatin given concurrently during definitive (and probably
also post-operative) radiotherapy provide the optimal drug
exposition, when toxicity and compliance issues are taken into
consideration. Nevertheless, it will remain unclear whether
the prolonged survival observed in retrospective analyses in
patients receiving a dose beyond the 200 mg/m2 is due
to the higher dose itself or because of a better general
condition, making it possible for them to receive an additional
cisplatin dose.
Clinical Practice Recommendations
The high rate of systemic and mucosal toxicities associated
with high-dose cisplatin during radiotherapy led many
trialists and clinicians to seek for alternative regimens
with diminished treatment-related complications, improved
compliance, and maintained anticancer activity. The theoretical
background for weekly cisplatin has been further enriched by
assumptions that compared with the high-dose schedule it has
a superior capacity (1) to facilitate timely dose adjustments,
(2) to enhance radiosensitization of the tumor, and (3) to
lower costs and increase the feasibility by being able to
administer this lower dose in the outpatient setting (8).
Further support for its use have been the positive results
obtained in patients with nasopharyngeal and uterine
cervical cancers treated with low-dose cisplatin-based
chemoradiotherapy (42, 43).
However, none of these claims have ever been based on
sufficient clinical evidence, and extrapolations from other disease
entities would have been unnecessary if a proper phase III trial
had been available. In order to offer the best possible care outside
clinical trials for the individual patient, taking into account what
can be considered optimal standard chemoradiation, i.e., 100
mg/m2 given three times at three-week intervals concurrently
with conventionally fractionated radiotherapy, three clinical
situations may arise:
1) There are absolute contraindications to use cisplatin (e.g.,
poor performance status, renal failure, overt acquired
immunodeficiency syndrome, pregnancy, or allergy to the
agent) (44). In this scenario, both high- and low-dose
regimens are excluded. In combination with definitive
radiotherapy, some of the viable alternatives supported
by randomized clinical research comprise carboplatin plus
fluorouracil or cetuximab (45–47). Other options based
on patient and disease characteristic include conventionally
fractionated radiotherapy alone in both settings and altered
fractionation radiotherapy, preferably hyperfractionation, in
the definitive disease setting (28, 48).
2) There are relative contraindications to use cisplatin (e.g.,
dysfunctions of various organs) (44). This clinical situation
represents the so-called gray zone in medical decision
making. Here, if no clear guidelines for dose reductions
exist, the relativity of the contraindications implies for some
practitioners the need of treatment modifications, while the
others might not permit any changes to the plan. We
believe that under these circumstances lowering the peak
concentration (which is an important determinant for acute
toxicity) by either a prolonged infusion or dose reduction
are defendable options (44, 49, 50). Alternatively, the options
mentioned above in the subsection on what to use in case of
absolute contraindications to cisplatin also hold for patients
with relative contraindications. Again, patient and disease
characteristics are crucial in decision making, and all aspects
should be discussed in the multidisciplinary tumor board.
3) There are no contraindications to use cisplatin. The patient is
in a good general condition, has no or few comorbidities and
is willing to adhere to the treatment program. The standard
approach in the definitive disease setting is to give two or
three cycles of high-dose cisplatin during altered fractionation
or conventional radiotherapy, respectively, which should be
pursued whenever possible. In the adjuvant setting, only
the latter radiotherapy fractionation is the current evidence-
based option. In addition, there is an important role for
the clinician, not only to stimulate patients to adhere to
the treatment schedule, but also to give him/her maximal
supportive care in order to make it tolerable for the
patient. A minimum cumulative cisplatin dose of 200 mg/m2
should be aimed for and when conventional fractionation
radiotherapy is used, the third cycle should only be given when
toxicity permits.
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CONCLUSIONS
The landscape of SCCHN has been undergoing important
epidemiologic transitions, which have notable impact on patient
outcome, disease classification, and will probably also diversify
treatment options. In economically developed countries, the
role of chemoradiation with three-weekly high-dose cisplatin
has been compromised by an ever growing number of HPV-
positive oropharyngeal cancer cases, with 5-years survival rates
even exceeding 80% in the more advanced disease settings
(according to the 7th AJCC classification), which entails potential
long term toxicities and therefore gives priority to de-escalation
strategies (39, 51). However, this de-escalation approach has
recently been brought into question by two large randomized
trials (37, 41). Moreover, in the rest of the world, in which the
majority of patients present with HPV-negative disease, facing
a more unfavorable outcome, optimal use of platinum-based
chemoradiation remains the cornerstone of the multi-modality
management in LA-SCCHN.
The primary take-home message of this review is that
repeatedly confirmed results of well-conducted, large,
randomized trials should be respected unless proven otherwise.
Second, the applicability of modern oncology research may be
limited in many parts of the world, for which improvements
in established treatment solutions are of potential value. And
third, weekly low-dose cisplatin is not superior to the three-
weekly high-dose regimen, which should therefore remain the
standard of concomitant chemotherapy during external beam
radiotherapy in LA-SCCHN.
In oncology, and this is certainly the case in head and neck
oncology, there is an urgent need for new treatment modalities
with high efficacy, low-toxicity, and ease of administration,
tailored to the individual patient. Particularly modern
immunotherapy supported by reliable predictive biomarkers
has the greatest potential to replace or act as an add-on to
present therapies. However, the downside is still its limited
accessibility and affordability and currently also the lack of data
in the locally advanced setting. Until this is resolved, the classical
chemoradiotherapy will preserve its global relevance.
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